The suit calls into focus one of the central issues at play: whether Mr. Ackman improperly built up his nearly 10 percent stake in Allergan as he prepared to make a bid with Valeant for Allergan.
via NYT > Business Day http://ift.tt/1xLeBxg
via WordPress http://ift.tt/1oeyUls
No comments:
Post a Comment